The investigators will conduct a phase 1 clinical study of placebo, 200 mg and 400 mg Oltipraz administered to 20 current smokers per group for 12 weeks. Endpoints of dosimetry will include DNA and hemoglobin adducts of benzo(a)pyrene-7,8-diol-9,10-epoxide in bronchoalveolar macrophages from lavage and epithelial cells from biopsy, and blood lymphocytes and oral mucosa cells. Endpoints will also include measurements of oxidation status, phase II enzymes activities, and 4-aminobiphenyl adducts in bladder lining cells. Correlations will be made with GSTM1 genotype. Tolerability and toxicity will be assessed.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN095135-000
Application #
6157694
Study Section
Project Start
1999-09-30
Project End
2001-09-29
Budget Start
1999-09-30
Budget End
2000-09-29
Support Year
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
Organized Research Units
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611